SCHEMBL3978078

SCHEMBL3978078

CCOC(=O)c1occ(-c2ccc(OC)cc2)c1-c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.51
KDM4E B2RXH2 4/20 0.51
GAA P10253 3/20 0.51
POLB P06746 2/20 0.51
HTT P42858 2/20 0.51
SMN1; SMN2 Q16637 4/20 0.49
TP53 P04637 3/20 0.49
MAPT P10636 3/20 0.49
LMNA P02545 3/20 0.49
TDP1 Q9NUW8 2/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
MEN1 O00255 1/20 0.49
HSP90AA1 P07900 1/20 0.49
MAPK1 P28482 1/20 0.49
MPI P34949 1/20 0.49
KMT2A Q03164 1/20 0.49
HKDC1 Q2TB90 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4282758 0.84 CDC7 (0.48) ALDH1A1KDM4EGAAPOLBSMN1; SMN2
SCHEMBL3982902 0.81 CA1 (0.46) ALDH1A1KDM4EGAAPOLBHTT
SCHEMBL3981475 0.81 GAA (0.45) ALDH1A1KDM4EGAASMN1; SMN2TP53
SCHEMBL3973642 0.81 MAPT (0.46) ALDH1A1KDM4EGAASMN1; SMN2TP53
SCHEMBL3977567 0.80 NR4A2 (0.51) ALDH1A1KDM4EPOLBSMN1; SMN2TP53
SCHEMBL3977063 0.79 LMNA (0.45) ALDH1A1HTTSMN1; SMN2MAPTLMNA
SCHEMBL3982581 0.78 PPARG (0.51) GAAMAPTMEN1HSP90AA1KMT2A
SCHEMBL3982596 0.78 PPARG (0.51) MAPTMEN1HSP90AA1KMT2APPARG
SCHEMBL3977290 0.77 MAPT (0.50) ALDH1A1KDM4EGAAHTTSMN1; SMN2
SCHEMBL3977049 0.77 ALDH1A1 (0.47) ALDH1A1KDM4EGAASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2122353-A1 SENSOR CRANFIELD UNIVERSITY (GB) 2009-11-25 EP disclosed
EP-2057116-A1 NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS Richter Gedeon NYRT (HU) 2009-05-13 EP disclosed
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
WO-2008107649-A1 SENSOR CRANFIELD UNIVERSITY (GB) 2008-09-12 WO disclosed
EP-1963332-A1 1 H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF Memory Pharmaceuticals Corporation (US) 2008-09-03 EP disclosed
WO-2008050167-A1 NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2008-05-02 WO disclosed
WO-2007056582-A1 1 H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF MEMORY PHARMACEUTICALS CORPORATION (US) 2007-05-18 WO disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 ALDH1A1 1389/4885KDM4E 2769/4885GAA 1023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.